img

Global Antiviral Drugs Industry Research Report, Growth Trends and Competitive Analysis 2024-2034


Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare

Publisher : MRA | Format : PDF

Global Antiviral Drugs Industry Research Report, Growth Trends and Competitive Analysis 2024-2034

Antiviral drugs are medicines that decrease the ability of flu viruses to reproduce. when used as directed, antiviral drugs may help reduce the duration of flu.
The global Antiviral Drugs market size was US$ 40870 million in 2022 and is forecast to a readjusted size of US$ 51390 million by 2034 with a CAGR of 3.3% during the forecast period 2024-2034.
In this market study, analysts have estimated the reverse transcriptase inhibitors to dominate the antiviral drugs market during the forecast period. These are compounds that are used to inhibit the reverse transcriptase enzyme. The capability of this enzyme to catalyze the process of conversion of viral RNA into DNA, to infect the healthy host cell and replicate it is the key contributor to the growth of this segment in the hiv treatment drugs market.
In terms of sales (consumption) side, this report focuses on the sales of Antiviral Drugs by regions (Countries), company, by type and by type. from 2018 to 2024 and forecast to 2034.
The global Antiviral Drugs market is thoroughly, accurately, and comprehensively assessed in the report with a large focus on market dynamics, market competition, regional growth, segmental analysis, and key growth strategies. Buyers of the report will have access to verified market figures, including global market size in terms of revenue and volume. As part of sales analysis, the authors of the report have provided reliable estimations and calculations for global revenue and sales by type segment of the global Antiviral Drugs market. These figures have been provided in terms of both revenue and sales for the period 2018-2034. Additionally, the report provides accurate figures for sales by region in terms of revenue as well as volume for the same period.



By Company


Roche
Johnson & Johnson
Merck
Novartis
Bristol-Myers Squibb
Gilead Sciences
GlaxoSmithKline
AbbVie
By Type
Reverse Transcriptase Inhibitors
Protease Inhibitors
Fusion Inhibitors
Immune System Modulators
By Application
Hepatitis Therapeutics
HIV/AIDS Therapeutics
Herpes Therapeutics
Influenza Therapeutics
Sales by Region
North America
U.S.
Canada
China
APAC (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
Europe
Germany
France
U.K.
Italy
Russia
Middle East, Africa, Latin America
Brazil
Mexico
Turkey
Israel
GCC Countries

Chapter Outline


Chapter 1Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2Sales (consumption), revenue of Antiviral Drugs in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 3Detailed analysis of Antiviral Drugs manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6North America by company, by type, by application and by country, sales, and revenue for each segment.
Chapter 7Europe by company, by type, by application and by country, sales, and revenue for each segment.
Chapter 8China by company, by type and by application, sales, and revenue for each segment.
Chapter 9APAC (excluding China) by company, by type, by application and by region, sales, and revenue for each segment.
Chapter 10Middle East, Africa, and Latin America by company, by type, by application and by country, sales, and revenue for each segment.
Chapter 11Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Antiviral Drugs sales, revenue, price, gross margin, and recent development, etc.
Chapter 12Analysis of industrial chain, sales channel, key raw materials, distributors, and customers.
Chapter 13Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 14The main points and conclusions of the report.

Table of Content

1 Report Overview
1.1 Antiviral Drugs Definition
1.2 Market by Type
1.2.1 Global Antiviral Drugs Market Size Growth Rate by Type, 2018 VS 2022 VS 2034
1.2.2 Reverse Transcriptase Inhibitors
1.2.3 Protease Inhibitors
1.2.4 Fusion Inhibitors
1.2.5 Immune System Modulators
1.3 Market Segment by Application
1.3.1 Global Antiviral Drugs Market Size Growth Rate by Application, 2018 VS 2022 VS 2034
1.3.2 Hepatitis Therapeutics
1.3.3 HIV/AIDS Therapeutics
1.3.4 Herpes Therapeutics
1.3.5 Influenza Therapeutics
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Antiviral Drugs Sales
2.1 Global Antiviral Drugs Revenue Estimates and Forecasts 2018-2034
2.2 Global Antiviral Drugs Revenue by Region: 2018 VS 2022 VS 2034
2.3 Global Antiviral Drugs Revenue by Region
2.3.1 Global Antiviral Drugs Revenue by Region (2018-2024)
2.3.2 Global Antiviral Drugs Revenue by Region (2024-2034)
2.4 Global Antiviral Drugs Sales Quantity Estimates and Forecasts 2018-2034
2.5 Global Antiviral Drugs Sales Quantity by Region: 2018 VS 2022 VS 2034
2.6 Global Antiviral Drugs Sales Quantity by Region
2.6.1 Global Antiviral Drugs Sales Quantity by Region (2018-2024)
2.6.2 Global Antiviral Drugs Sales Quantity by Region (2024-2034)
2.7 North America
2.8 Europe
2.9 China
2.10 APAC (excluding China)
2.11 Middle East, Africa and Latin America
3 Competition by Manufacturers
3.1 Global Antiviral Drugs Sales Quantity by Manufacturers
3.1.1 Global Antiviral Drugs Sales Quantity by Manufacturers (2018-2024)
3.1.2 Global Antiviral Drugs Sales Quantity Share by Manufacturers (2018-2024)
3.1.3 Global Top 10 and Top 5 Companies by Antiviral Drugs Sales in 2022
3.2 Global Antiviral Drugs Revenue by Manufacturers
3.2.1 Global Antiviral Drugs Revenue by Manufacturers (2018-2024)
3.2.2 Global Antiviral Drugs Revenue Share by Manufacturers (2018-2024)
3.2.3 Global Top 10 and Top 5 Companies by Antiviral Drugs Revenue in 2022
3.3 Global Antiviral Drugs Sales Price by Manufacturers
3.4 Global Key Players of Antiviral Drugs, Industry Ranking, 2021 VS 2022
3.5 Analysis of Competitive Landscape
3.5.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.5.2 Global Antiviral Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.6 Global Key Manufacturers of Antiviral Drugs, Manufacturing Base Distribution and Headquarters
3.7 Global Key Manufacturers of Antiviral Drugs, Product Offered and Application
3.8 Global Key Manufacturers of Antiviral Drugs, Date of Enter into This Industry
3.9 Mergers & Acquisitions, Expansion Plans
4 Estimates and Forecasts by Type
4.1 Global Antiviral Drugs Sales Quantity by Type
4.1.1 Global Antiviral Drugs Historical Sales Quantity by Type (2018-2024)
4.1.2 Global Antiviral Drugs Forecasted Sales Quantity by Type (2024-2034)
4.1.3 Global Antiviral Drugs Sales Quantity Market Share by Type (2018-2034)
4.2 Global Antiviral Drugs Revenue by Type
4.2.1 Global Antiviral Drugs Historical Revenue by Type (2018-2024)
4.2.2 Global Antiviral Drugs Forecasted Revenue by Type (2024-2034)
4.2.3 Global Antiviral Drugs Revenue Market Share by Type (2018-2034)
4.3 Global Antiviral Drugs Price by Type
4.3.1 Global Antiviral Drugs Price by Type (2018-2024)
4.3.2 Global Antiviral Drugs Price Forecast by Type (2024-2034)
5 Market Size by Application
5.1 Global Antiviral Drugs Sales Quantity by Application
5.1.1 Global Antiviral Drugs Historical Sales Quantity by Application (2018-2024)
5.1.2 Global Antiviral Drugs Forecasted Sales Quantity by Application (2024-2034)
5.1.3 Global Antiviral Drugs Sales Quantity Market Share by Application (2018-2034)
5.2 Global Antiviral Drugs Revenue by Application
5.2.1 Global Antiviral Drugs Historical Revenue by Application (2018-2024)
5.2.2 Global Antiviral Drugs Forecasted Revenue by Application (2024-2034)
5.2.3 Global Antiviral Drugs Revenue Market Share by Application (2018-2034)
5.3 Global Antiviral Drugs Price by Application
5.3.1 Global Antiviral Drugs Price by Application (2018-2024)
5.3.2 Global Antiviral Drugs Price Forecast by Application (2024-2034)
6 North America
6.1 North America Antiviral Drugs Sales by Company
6.1.1 North America Antiviral Drugs Revenue by Company (2018-2024)
6.1.2 North America Antiviral Drugs Sales Quantity by Company (2018-2024)
6.2 North America Antiviral Drugs Market Size by Type
6.2.1 North America Antiviral Drugs Sales Quantity by Type (2018-2034)
6.2.2 North America Antiviral Drugs Revenue by Type (2018-2034)
6.3 North America Antiviral Drugs Market Size by Application
6.3.1 North America Antiviral Drugs Sales Quantity by Application (2018-2034)
6.3.2 North America Antiviral Drugs Revenue by Application (2018-2034)
6.4 North America Antiviral Drugs Market Size by Country
6.4.1 North America Antiviral Drugs Revenue by Country: 2018 VS 2022 VS 2034
6.4.2 North America Antiviral Drugs Revenue by Country (2018-2034)
6.4.3 North America Antiviral Drugs Sales Quantity by Country (2018-2034)
6.4.4 U.S.
6.4.5 Canada
7 Europe
7.1 Europe Antiviral Drugs Sales by Company
7.1.1 Europe Antiviral Drugs Sales Quantity by Company (2018-2024)
7.1.2 Europe Antiviral Drugs Revenue by Company (2018-2024)
7.2 Europe Antiviral Drugs Market Size by Type
7.2.1 Europe Antiviral Drugs Sales Quantity by Type (2018-2034)
7.2.2 Europe Antiviral Drugs Revenue by Type (2018-2034)
7.3 Europe Antiviral Drugs Market Size by Application
7.3.1 Europe Antiviral Drugs Sales Quantity by Application (2018-2034)
7.3.2 Europe Antiviral Drugs Revenue by Application (2018-2034)
7.4 Europe Antiviral Drugs Market Size by Country
7.4.1 Europe Antiviral Drugs Revenue by Country: 2018 VS 2022 VS 2034
7.4.2 Europe Antiviral Drugs Revenue by Country (2018-2034)
7.4.3 Europe Antiviral Drugs Sales Quantity by Country (2018-2034)
7.4.4 Germany
7.4.5 France
7.4.6 U.K.
7.4.7 Italy
7.4.8 Russia
8 China
8.1 China Antiviral Drugs Sales by Company
8.1.1 China Antiviral Drugs Sales Quantity by Company (2018-2024)
8.1.2 China Antiviral Drugs Revenue by Company (2018-2024)
8.2 China Antiviral Drugs Market Size by Type
8.2.1 China Antiviral Drugs Sales Quantity by Type (2018-2034)
8.2.2 China Antiviral Drugs Revenue by Type (2018-2034)
8.3 China Antiviral Drugs Market Size by Application
8.3.1 China Antiviral Drugs Sales Quantity by Application (2018-2034)
8.3.2 China Antiviral Drugs Revenue by Application (2018-2034)
9 APAC (excluding China)
9.1 APAC Antiviral Drugs Sales by Company
9.1.1 APAC Antiviral Drugs Sales Quantity by Company (2018-2024)
9.1.2 APAC Antiviral Drugs Revenue by Company (2018-2024)
9.2 APAC Antiviral Drugs Market Size by Type
9.2.1 APAC Antiviral Drugs Sales Quantity by Type (2018-2034)
9.2.2 APAC Antiviral Drugs Revenue by Type (2018-2034)
9.3 APAC Antiviral Drugs Market Size by Application
9.3.1 APAC Antiviral Drugs Sales Quantity by Application (2018-2034)
9.3.2 APAC Antiviral Drugs Revenue by Application (2018-2034)
9.4 APAC Antiviral Drugs Market Size by Region
9.4.1 APAC Antiviral Drugs Revenue by Region: 2018 VS 2022 VS 2034
9.4.2 APAC Antiviral Drugs Revenue by Region (2018-2034)
9.4.3 APAC Antiviral Drugs Sales Quantity by Region (2018-2034)
9.4.4 Japan
9.4.5 South Korea
9.4.6 China Taiwan
9.4.7 Southeast Asia
9.4.8 India
10 Middle East, Africa and Latin America
10.1 Middle East, Africa and Latin America Antiviral Drugs Sales by Company
10.1.1 Middle East, Africa and Latin America Antiviral Drugs Sales Quantity by Company (2018-2024)
10.1.2 Middle East, Africa and Latin America Antiviral Drugs Revenue by Company (2018-2024)
10.2 Middle East, Africa and Latin America Antiviral Drugs Market Size by Type
10.2.1 Middle East, Africa and Latin America Antiviral Drugs Sales Quantity by Type (2018-2034)
10.2.2 Middle East, Africa and Latin America Antiviral Drugs Revenue by Type (2018-2034)
10.3 Middle East, Africa and Latin America Antiviral Drugs Market Size by Application
10.3.1 Middle East, Africa and Latin America Antiviral Drugs Sales Quantity by Application (2018-2034)
10.3.2 Middle East, Africa and Latin America Antiviral Drugs Revenue by Application (2018-2034)
10.4 Middle East, Africa and Latin America Antiviral Drugs Market Size by Country
10.4.1 Middle East, Africa and Latin America Antiviral Drugs Revenue by Country: 2018 VS 2022 VS 2034
10.4.2 Middle East, Africa and Latin America Antiviral Drugs Revenue by Country (2018-2034)
10.4.3 Middle East, Africa and Latin America Antiviral Drugs Sales Quantity by Country (2018-2034)
10.4.4 Brazil
10.4.5 Mexico
10.4.6 Turkey
10.4.7 Israel
10.4.8 GCC Countries
11 Company Profiles
11.1 Roche
11.1.1 Roche Company Information
11.1.2 Roche Overview
11.1.3 Roche Antiviral Drugs Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.1.4 Roche Antiviral Drugs Products and Services
11.1.5 Roche Antiviral Drugs SWOT Analysis
11.1.6 Roche Recent Developments
11.2 Johnson & Johnson
11.2.1 Johnson & Johnson Company Information
11.2.2 Johnson & Johnson Overview
11.2.3 Johnson & Johnson Antiviral Drugs Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.2.4 Johnson & Johnson Antiviral Drugs Products and Services
11.2.5 Johnson & Johnson Antiviral Drugs SWOT Analysis
11.2.6 Johnson & Johnson Recent Developments
11.3 Merck
11.3.1 Merck Company Information
11.3.2 Merck Overview
11.3.3 Merck Antiviral Drugs Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.3.4 Merck Antiviral Drugs Products and Services
11.3.5 Merck Antiviral Drugs SWOT Analysis
11.3.6 Merck Recent Developments
11.4 Novartis
11.4.1 Novartis Company Information
11.4.2 Novartis Overview
11.4.3 Novartis Antiviral Drugs Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.4.4 Novartis Antiviral Drugs Products and Services
11.4.5 Novartis Antiviral Drugs SWOT Analysis
11.4.6 Novartis Recent Developments
11.5 Bristol-Myers Squibb
11.5.1 Bristol-Myers Squibb Company Information
11.5.2 Bristol-Myers Squibb Overview
11.5.3 Bristol-Myers Squibb Antiviral Drugs Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.5.4 Bristol-Myers Squibb Antiviral Drugs Products and Services
11.5.5 Bristol-Myers Squibb Antiviral Drugs SWOT Analysis
11.5.6 Bristol-Myers Squibb Recent Developments
11.6 Gilead Sciences
11.6.1 Gilead Sciences Company Information
11.6.2 Gilead Sciences Overview
11.6.3 Gilead Sciences Antiviral Drugs Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.6.4 Gilead Sciences Antiviral Drugs Products and Services
11.6.5 Gilead Sciences Antiviral Drugs SWOT Analysis
11.6.6 Gilead Sciences Recent Developments
11.7 GlaxoSmithKline
11.7.1 GlaxoSmithKline Company Information
11.7.2 GlaxoSmithKline Overview
11.7.3 GlaxoSmithKline Antiviral Drugs Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.7.4 GlaxoSmithKline Antiviral Drugs Products and Services
11.7.5 GlaxoSmithKline Antiviral Drugs SWOT Analysis
11.7.6 GlaxoSmithKline Recent Developments
11.8 AbbVie
11.8.1 AbbVie Company Information
11.8.2 AbbVie Overview
11.8.3 AbbVie Antiviral Drugs Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.8.4 AbbVie Antiviral Drugs Products and Services
11.8.5 AbbVie Antiviral Drugs SWOT Analysis
11.8.6 AbbVie Recent Developments
12 Value Chain and Sales Channels Analysis
12.1 Antiviral Drugs Value Chain Analysis
12.2 Antiviral Drugs Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Antiviral Drugs Production Mode & Process
12.4 Antiviral Drugs Sales and Marketing
12.4.1 Antiviral Drugs Sales Channels
12.4.2 Antiviral Drugs Distributors
12.5 Antiviral Drugs Customers
13 Market Dynamics
13.1 Antiviral Drugs Industry Trends
13.2 Antiviral Drugs Market Drivers
13.3 Antiviral Drugs Market Challenges
13.4 Antiviral Drugs Market Restraints
14 Key Findings
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer

List of Figure

List of Tables
Table 1. Global Antiviral Drugs Market Size Growth Rate (CAGR) by Type, 2018 VS 2022 VS 2034 (US$ Million)
Table 2. Major Manufacturers of Reverse Transcriptase Inhibitors
Table 3. Major Manufacturers of Protease Inhibitors
Table 4. Major Manufacturers of Fusion Inhibitors
Table 5. Major Manufacturers of Immune System Modulators
Table 6. Global Antiviral Drugs Market Size Growth Rate (CAGR) by Application, 2018 VS 2022 VS 2034 (US$ Million)
Table 7. Global Antiviral Drugs Revenue by Region: 2018 VS 2022 VS 2034 (US$ Million)
Table 8. Global Antiviral Drugs Revenue by Region (2018-2024) & (US$ Million)
Table 9. Global Antiviral Drugs Revenue Market Share by Region (2018-2024)
Table 10. Global Antiviral Drugs Revenue by Region (2024-2034) & (US$ Million)
Table 11. Global Antiviral Drugs Revenue Market Share by Region (2024-2034)
Table 12. Global Antiviral Drugs Sales Quantity by Region: 2018 VS 2022 VS 2034 (K Units)
Table 13. Global Antiviral Drugs Sales by Region (2018-2024) & (K Units)
Table 14. Global Antiviral Drugs Sales Market Share by Region (2018-2024)
Table 15. Global Antiviral Drugs Sales by Region (2024-2034) & (K Units)
Table 16. Global Antiviral Drugs Sales Market Share by Region (2024-2034)
Table 17. Global Antiviral Drugs Sales Quantity by Manufacturers (2018-2024) & (K Units)
Table 18. Global Antiviral Drugs Sales Quantity Share by Manufacturers (2018-2024)
Table 19. Global Antiviral Drugs Revenue by Manufacturers (2018-2024) & (US$ Million)
Table 20. Global Antiviral Drugs Revenue Share by Manufacturers (2018-2024)
Table 21. Global Antiviral Drugs Price by Manufacturers 2018-2024 (USD/Unit)
Table 22. Global Key Players of Antiviral Drugs, Industry Ranking, 2021 VS 2022
Table 23. Global Antiviral Drugs Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 24. Global Antiviral Drugs by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Antiviral Drugs as of 2022)
Table 25. Global Key Manufacturers of Antiviral Drugs, Manufacturing Base Distribution and Headquarters
Table 26. Global Key Manufacturers of Antiviral Drugs, Product Offered and Application
Table 27. Global Key Manufacturers of Antiviral Drugs, Date of Enter into This Industry
Table 28. Mergers & Acquisitions, Expansion Plans
Table 29. Global Antiviral Drugs Sales Quantity by Type (2018-2024) & (K Units)
Table 30. Global Antiviral Drugs Sales Quantity by Type (2024-2034) & (K Units)
Table 31. Global Antiviral Drugs Sales Quantity Share by Type (2018-2024)
Table 32. Global Antiviral Drugs Sales Quantity Share by Type (2024-2034)
Table 33. Global Antiviral Drugs Revenue by Type (2018-2024) & (US$ Million)
Table 34. Global Antiviral Drugs Revenue by Type (2024-2034) & (US$ Million)
Table 35. Global Antiviral Drugs Revenue Share by Type (2018-2024)
Table 36. Global Antiviral Drugs Revenue Share by Type (2024-2034)
Table 37. Antiviral Drugs Price by Type (2018-2024) & (USD/Unit)
Table 38. Global Antiviral Drugs Price Forecast by Type (2024-2034) & (USD/Unit)
Table 39. Global Antiviral Drugs Sales Quantity by Application (2018-2024) & (K Units)
Table 40. Global Antiviral Drugs Sales Quantity by Application (2024-2034) & (K Units)
Table 41. Global Antiviral Drugs Sales Quantity Share by Application (2018-2024)
Table 42. Global Antiviral Drugs Sales Quantity Share by Application (2024-2034)
Table 43. Global Antiviral Drugs Revenue by Application (2018-2024) & (US$ Million)
Table 44. Global Antiviral Drugs Revenue by Application (2024-2034) & (US$ Million)
Table 45. Global Antiviral Drugs Revenue Share by Application (2018-2024)
Table 46. Global Antiviral Drugs Revenue Share by Application (2024-2034)
Table 47. Antiviral Drugs Price by Application (2018-2024) & (USD/Unit)
Table 48. Global Antiviral Drugs Price Forecast by Application (2024-2034) & (USD/Unit)
Table 49. North America Antiviral Drugs Revenue by Company (2018-2024) & (US$ Million)
Table 50. North America Antiviral Drugs Sales Quantity by Company (2018-2024) & (K Units)
Table 51. North America Antiviral Drugs Sales Quantity by Type (2018-2024) & (K Units)
Table 52. North America Antiviral Drugs Sales Quantity by Type (2024-2034) & (K Units)
Table 53. North America Antiviral Drugs Revenue by Type (2018-2024) & (US$ Million)
Table 54. North America Antiviral Drugs Revenue by Type (2024-2034) & (US$ Million)
Table 55. North America Antiviral Drugs Sales Quantity by Application (2018-2024) & (K Units)
Table 56. North America Antiviral Drugs Sales Quantity by Application (2024-2034) & (K Units)
Table 57. North America Antiviral Drugs Revenue by Application (2018-2024) & (US$ Million)
Table 58. North America Antiviral Drugs Revenue by Application (2024-2034) & (US$ Million)
Table 59. North America Antiviral Drugs Revenue by Country: 2018 VS 2022 VS 2034 (US$ Million)
Table 60. North America Antiviral Drugs Revenue by Country (2018-2024) & (US$ Million)
Table 61. North America Antiviral Drugs Revenue by Country (2024-2034) & (US$ Million)
Table 62. North America Antiviral Drugs Sales Quantity by Country (2018-2024) & (K Units)
Table 63. North America Antiviral Drugs Sales Quantity by Country (2024-2034) & (K Units)
Table 64. Europe Antiviral Drugs Sales Quantity by Company (2018-2024) & (K Units)
Table 65. Europe Antiviral Drugs Revenue by Company (2018-2024) & (US$ Million)
Table 66. Europe Antiviral Drugs Sales Quantity by Type (2018-2024) & (K Units)
Table 67. Europe Antiviral Drugs Sales Quantity by Type (2024-2034) & (K Units)
Table 68. Europe Antiviral Drugs Revenue by Type (2018-2024) & (US$ Million)
Table 69. Europe Antiviral Drugs Revenue by Type (2024-2034) & (US$ Million)
Table 70. Europe Antiviral Drugs Sales Quantity by Application (2018-2024) & (K Units)
Table 71. Europe Antiviral Drugs Sales Quantity by Application (2024-2034) & (K Units)
Table 72. Europe Antiviral Drugs Revenue by Application (2018-2024) & (US$ Million)
Table 73. Europe Antiviral Drugs Revenue by Application (2024-2034) & (US$ Million)
Table 74. Europe Antiviral Drugs Revenue by Country: 2018 VS 2022 VS 2034 (US$ Million)
Table 75. Europe Antiviral Drugs Revenue by Country (2018-2024) & (US$ Million)
Table 76. Europe Antiviral Drugs Revenue by Country (2024-2034) & (US$ Million)
Table 77. Europe Antiviral Drugs Sales Quantity by Country (2018-2024) & (K Units)
Table 78. Europe Antiviral Drugs Sales Quantity by Country (2024-2034) & (K Units)
Table 79. China Antiviral Drugs Sales Quantity by Company (2018-2024) & (K Units)
Table 80. China Antiviral Drugs Revenue by Company (2018-2024) & (US$ Million)
Table 81. China Antiviral Drugs Sales Quantity by Type (2018-2024) & (K Units)
Table 82. China Antiviral Drugs Sales Quantity by Type (2024-2034) & (K Units)
Table 83. China Antiviral Drugs Revenue by Type (2018-2024) & (US$ Million)
Table 84. China Antiviral Drugs Revenue by Type (2024-2034) & (US$ Million)
Table 85. China Antiviral Drugs Sales Quantity by Application (2018-2024) & (K Units)
Table 86. China Antiviral Drugs Sales Quantity by Application (2024-2034) & (K Units)
Table 87. China Antiviral Drugs Revenue by Application (2018-2024) & (US$ Million)
Table 88. China Antiviral Drugs Revenue by Application (2024-2034) & (US$ Million)
Table 89. APAC Antiviral Drugs Sales Quantity by Company (2018-2024) & (K Units)
Table 90. APAC Antiviral Drugs Revenue by Company (2018-2024) & (US$ Million)
Table 91. APAC Antiviral Drugs Sales Quantity by Type (2018-2024) & (K Units)
Table 92. APAC Antiviral Drugs Sales Quantity by Type (2024-2034) & (K Units)
Table 93. APAC Antiviral Drugs Revenue by Type (2018-2024) & (US$ Million)
Table 94. APAC Antiviral Drugs Revenue by Type (2024-2034) & (US$ Million)
Table 95. APAC Antiviral Drugs Sales Quantity by Application (2018-2024) & (K Units)
Table 96. APAC Antiviral Drugs Sales Quantity by Application (2024-2034) & (K Units)
Table 97. APAC Antiviral Drugs Revenue by Application (2018-2024) & (US$ Million)
Table 98. APAC Antiviral Drugs Revenue by Application (2024-2034) & (US$ Million)
Table 99. APAC Antiviral Drugs Revenue by Region: 2018 VS 2022 VS 2034 (US$ Million)
Table 100. APAC Antiviral Drugs Revenue by Region (2018-2024) & (US$ Million)
Table 101. APAC Antiviral Drugs Revenue by Region (2024-2034) & (US$ Million)
Table 102. APAC Antiviral Drugs Sales Quantity by Region (2018-2024) & (K Units)
Table 103. APAC Antiviral Drugs Sales Quantity by Region (2024-2034) & (K Units)
Table 104. Middle East, Africa and Latin America Antiviral Drugs Sales Quantity by Company (2018-2024) & (K Units)
Table 105. Middle East, Africa and Latin America Antiviral Drugs Revenue by Company (2018-2024) & (US$ Million)
Table 106. Middle East, Africa and Latin America Antiviral Drugs Sales Quantity by Type (2018-2024) & (K Units)
Table 107. Middle East, Africa and Latin America Antiviral Drugs Sales Quantity by Type (2024-2034) & (K Units)
Table 108. Middle East, Africa and Latin America Antiviral Drugs Revenue by Type (2018-2024) & (US$ Million)
Table 109. Middle East, Africa and Latin America Antiviral Drugs Revenue by Type (2024-2034) & (US$ Million)
Table 110. Middle East, Africa and Latin America Antiviral Drugs Sales Quantity by Application (2018-2024) & (K Units)
Table 111. Middle East, Africa and Latin America Antiviral Drugs Sales Quantity by Application (2024-2034) & (K Units)
Table 112. Middle East, Africa and Latin America Antiviral Drugs Revenue by Application (2018-2024) & (US$ Million)
Table 113. Middle East, Africa and Latin America Antiviral Drugs Revenue by Application (2024-2034) & (US$ Million)
Table 114. Middle East, Africa and Latin America Antiviral Drugs Revenue by Country: 2018 VS 2022 VS 2034 (US$ Million)
Table 115. Middle East, Africa and Latin America Antiviral Drugs Revenue by Country (2018-2024) & (US$ Million)
Table 116. Middle East, Africa and Latin America Antiviral Drugs Revenue by Country (2024-2034) & (US$ Million)
Table 117. Middle East, Africa and Latin America Antiviral Drugs Sales Quantity by Country (2018-2024) & (K Units)
Table 118. Middle East, Africa and Latin America Antiviral Drugs Sales Quantity by Country (2024-2034) & (K Units)
Table 119. Roche Company Information
Table 120. Roche Description and Overview
Table 121. Roche Antiviral Drugs Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2018-2024)
Table 122. Roche Antiviral Drugs Product and Services
Table 123. Roche Antiviral Drugs SWOT Analysis
Table 124. Roche Recent Developments
Table 125. Johnson & Johnson Company Information
Table 126. Johnson & Johnson Description and Overview
Table 127. Johnson & Johnson Antiviral Drugs Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2018-2024)
Table 128. Johnson & Johnson Antiviral Drugs Product and Services
Table 129. Johnson & Johnson Antiviral Drugs SWOT Analysis
Table 130. Johnson & Johnson Recent Developments
Table 131. Merck Company Information
Table 132. Merck Description and Overview
Table 133. Merck Antiviral Drugs Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2018-2024)
Table 134. Merck Antiviral Drugs Product and Services
Table 135. Merck Antiviral Drugs SWOT Analysis
Table 136. Merck Recent Developments
Table 137. Novartis Company Information
Table 138. Novartis Description and Overview
Table 139. Novartis Antiviral Drugs Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2018-2024)
Table 140. Novartis Antiviral Drugs Product and Services
Table 141. Novartis Antiviral Drugs SWOT Analysis
Table 142. Novartis Recent Developments
Table 143. Bristol-Myers Squibb Company Information
Table 144. Bristol-Myers Squibb Description and Overview
Table 145. Bristol-Myers Squibb Antiviral Drugs Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2018-2024)
Table 146. Bristol-Myers Squibb Antiviral Drugs Product and Services
Table 147. Bristol-Myers Squibb Antiviral Drugs SWOT Analysis
Table 148. Bristol-Myers Squibb Recent Developments
Table 149. Gilead Sciences Company Information
Table 150. Gilead Sciences Description and Overview
Table 151. Gilead Sciences Antiviral Drugs Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2018-2024)
Table 152. Gilead Sciences Antiviral Drugs Product and Services
Table 153. Gilead Sciences Antiviral Drugs SWOT Analysis
Table 154. Gilead Sciences Recent Developments
Table 155. GlaxoSmithKline Company Information
Table 156. GlaxoSmithKline Description and Overview
Table 157. GlaxoSmithKline Antiviral Drugs Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2018-2024)
Table 158. GlaxoSmithKline Antiviral Drugs Product and Services
Table 159. GlaxoSmithKline Antiviral Drugs SWOT Analysis
Table 160. GlaxoSmithKline Recent Developments
Table 161. AbbVie Company Information
Table 162. AbbVie Description and Overview
Table 163. AbbVie Antiviral Drugs Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2018-2024)
Table 164. AbbVie Antiviral Drugs Product and Services
Table 165. AbbVie Antiviral Drugs SWOT Analysis
Table 166. AbbVie Recent Developments
Table 167. Key Raw Materials Lists
Table 168. Raw Materials Key Suppliers Lists
Table 169. Antiviral Drugs Distributors List
Table 170. Antiviral Drugs Customers List
Table 171. Antiviral Drugs Market Trends
Table 172. Antiviral Drugs Market Drivers
Table 173. Antiviral Drugs Market Challenges
Table 174. Antiviral Drugs Market Restraints
Table 175. Research Programs/Design for This Report
Table 176. Key Data Information from Secondary Sources
Table 177. Key Data Information from Primary Sources
List of Figures
Figure 1. Antiviral Drugs Product Picture
Figure 2. Global Antiviral Drugs Market Size Growth Rate by Type, 2018 VS 2022 VS 2034 (US$ Million)
Figure 3. Global Antiviral Drugs Market Share by Type in 2022 & 2034
Figure 4. Reverse Transcriptase Inhibitors Product Picture
Figure 5. Protease Inhibitors Product Picture
Figure 6. Fusion Inhibitors Product Picture
Figure 7. Immune System Modulators Product Picture
Figure 8. Global Antiviral Drugs Market Size Growth Rate by Application, 2018 VS 2022 VS 2034 (US$ Million)
Figure 9. Global Antiviral Drugs Market Share by Application in 2022 & 2034
Figure 10. Hepatitis Therapeutics
Figure 11. HIV/AIDS Therapeutics
Figure 12. Herpes Therapeutics
Figure 13. Influenza Therapeutics
Figure 14. Antiviral Drugs Report Years Considered
Figure 15. Global Antiviral Drugs Revenue, (US$ Million), 2018 VS 2022 VS 2034
Figure 16. Global Antiviral Drugs Revenue 2018-2034 (US$ Million)
Figure 17. Global Antiviral Drugs Revenue Market Share by Region in Percentage: 2022 Versus 2034
Figure 18. Global Antiviral Drugs Sales Quantity 2018-2034 (K Units)
Figure 19. Global Antiviral Drugs Sales Quantity Market Share by Region (2018-2024)
Figure 20. Global Antiviral Drugs Sales Quantity Market Share by Region (2024-2034)
Figure 21. North America Antiviral Drugs Sales Quantity YoY (2018-2034) & (K Units)
Figure 22. North America Antiviral Drugs Revenue YoY (2018-2034) & (US$ Million)
Figure 23. Europe Antiviral Drugs Sales Quantity YoY (2018-2034) & (K Units)
Figure 24. Europe Antiviral Drugs Revenue YoY (2018-2034) & (US$ Million)
Figure 25. China Antiviral Drugs Sales Quantity YoY (2018-2034) & (K Units)
Figure 26. China Antiviral Drugs Revenue YoY (2018-2034) & (US$ Million)
Figure 27. APAC Antiviral Drugs Sales Quantity YoY (2018-2034) & (K Units)
Figure 28. APAC Antiviral Drugs Revenue YoY (2018-2034) & (US$ Million)
Figure 29. Middle East, Africa and Latin America Antiviral Drugs Sales Quantity YoY (2018-2034) & (K Units)
Figure 30. Middle East, Africa and Latin America Antiviral Drugs Revenue YoY (2018-2034) & (US$ Million)
Figure 31. The Top 10 and Top 5 Players Market Share by Antiviral Drugs Sales Quantity in 2022
Figure 32. The Top 10 and Top 5 Players Market Share by Antiviral Drugs Revenue in 2022
Figure 33. Antiviral Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2018 VS 2022
Figure 34. Global Antiviral Drugs Sales Quantity Market Share by Type (2018-2034)
Figure 35. Global Antiviral Drugs Revenue Market Share by Type (2018-2034)
Figure 36. Global Antiviral Drugs Sales Quantity Market Share by Application (2018-2034)
Figure 37. Global Antiviral Drugs Revenue Market Share by Application (2018-2034)
Figure 38. North America Antiviral Drugs Revenue Market Share by Company in 2022
Figure 39. North America Antiviral Drugs Sales Quantity Market Share by Company in 2022
Figure 40. North America Antiviral Drugs Sales Quantity Market Share by Type (2018-2034)
Figure 41. North America Antiviral Drugs Revenue Market Share by Type (2018-2034)
Figure 42. North America Antiviral Drugs Sales Quantity Market Share by Application (2018-2034)
Figure 43. North America Antiviral Drugs Revenue Market Share by Application (2018-2034)
Figure 44. North America Antiviral Drugs Revenue Share by Country (2018-2034)
Figure 45. North America Antiviral Drugs Sales Quantity Share by Country (2018-2034)
Figure 46. U.S. Antiviral Drugs Revenue (2018-2034) & (US$ Million)
Figure 47. Canada Antiviral Drugs Revenue (2018-2034) & (US$ Million)
Figure 48. Europe Antiviral Drugs Sales Quantity Market Share by Company in 2022
Figure 49. Europe Antiviral Drugs Revenue Market Share by Company in 2022
Figure 50. Europe Antiviral Drugs Sales Quantity Market Share by Type (2018-2034)
Figure 51. Europe Antiviral Drugs Revenue Market Share by Type (2018-2034)
Figure 52. Europe Antiviral Drugs Sales Quantity Market Share by Application (2018-2034)
Figure 53. Europe Antiviral Drugs Revenue Market Share by Application (2018-2034)
Figure 54. Europe Antiviral Drugs Revenue Share by Country (2018-2034)
Figure 55. Europe Antiviral Drugs Sales Quantity Share by Country (2018-2034)
Figure 56. Germany Antiviral Drugs Revenue (2018-2034) & (US$ Million)
Figure 57. France Antiviral Drugs Revenue (2018-2034) & (US$ Million)
Figure 58. U.K. Antiviral Drugs Revenue (2018-2034) & (US$ Million)
Figure 59. Italy Antiviral Drugs Revenue (2018-2034) & (US$ Million)
Figure 60. Russia Antiviral Drugs Revenue (2018-2034) & (US$ Million)
Figure 61. China Antiviral Drugs Sales Quantity Market Share by Company in 2022
Figure 62. China Antiviral Drugs Revenue Market Share by Company in 2022
Figure 63. China Antiviral Drugs Sales Quantity Market Share by Type (2018-2034)
Figure 64. China Antiviral Drugs Revenue Market Share by Type (2018-2034)
Figure 65. China Antiviral Drugs Sales Quantity Market Share by Application (2018-2034)
Figure 66. China Antiviral Drugs Revenue Market Share by Application (2018-2034)
Figure 67. APAC Antiviral Drugs Sales Quantity Market Share by Company in 2022
Figure 68. APAC Antiviral Drugs Revenue Market Share by Company in 2022
Figure 69. APAC Antiviral Drugs Sales Quantity Market Share by Type (2018-2034)
Figure 70. APAC Antiviral Drugs Revenue Market Share by Type (2018-2034)
Figure 71. APAC Antiviral Drugs Sales Quantity Market Share by Application (2018-2034)
Figure 72. APAC Antiviral Drugs Revenue Market Share by Application (2018-2034)
Figure 73. APAC Antiviral Drugs Revenue Share by Region (2018-2034)
Figure 74. APAC Antiviral Drugs Sales Quantity Share by Region (2018-2034)
Figure 75. Japan Antiviral Drugs Revenue (2018-2034) & (US$ Million)
Figure 76. South Korea Antiviral Drugs Revenue (2018-2034) & (US$ Million)
Figure 77. China Taiwan Antiviral Drugs Revenue (2018-2034) & (US$ Million)
Figure 78. Southeast Asia Antiviral Drugs Revenue (2018-2034) & (US$ Million)
Figure 79. India Antiviral Drugs Revenue (2018-2034) & (US$ Million)
Figure 80. Middle East, Africa and Latin America Antiviral Drugs Sales Quantity Market Share by Company in 2022
Figure 81. Middle East, Africa and Latin America Antiviral Drugs Revenue Market Share by Company in 2022
Figure 82. Middle East, Africa and Latin America Antiviral Drugs Sales Quantity Market Share by Type (2018-2034)
Figure 83. Middle East, Africa and Latin America Antiviral Drugs Revenue Market Share by Type (2018-2034)
Figure 84. Middle East, Africa and Latin America Antiviral Drugs Sales Quantity Market Share by Application (2018-2034)
Figure 85. Middle East, Africa and Latin America Antiviral Drugs Revenue Market Share by Application (2018-2034)
Figure 86. Middle East, Africa and Latin America Antiviral Drugs Sales Quantity Share by Country (2018-2034)
Figure 87. Middle East, Africa and Latin America Antiviral Drugs Revenue Share by Country (2018-2034)
Figure 88. Brazil Antiviral Drugs Revenue (2018-2034) & (US$ Million)
Figure 89. Mexico Antiviral Drugs Revenue (2018-2034) & (US$ Million)
Figure 90. Turkey Antiviral Drugs Revenue (2018-2034) & (US$ Million)
Figure 91. Israel Antiviral Drugs Revenue (2018-2034) & (US$ Million)
Figure 92. GCC Countries Antiviral Drugs Revenue (2018-2034) & (US$ Million)
Figure 93. Antiviral Drugs Value Chain
Figure 94. Antiviral Drugs Production Process
Figure 95. Channels of Distribution (Direct Vs Distribution)
Figure 96. Distributors Profiles
Figure 97. Bottom-up and Top-down Approaches for This Report
Figure 98. Data Triangulation
Figure 99. Key Executives Interviewed